论文部分内容阅读
目的分析自体纯化CD34+细胞移植治疗中/高危淋巴细胞来源恶性肿瘤的临床疗效。方法 10名中/高危组淋巴细胞来源恶性肿瘤患者行自体纯化CD34+细胞移植治疗,细胞分选采用cliniMACS系统。计算并统计分选纯度和CD34+细胞回收率,观察移植相关并发症及患者生存情况。结果纯化后CD34+细胞纯度为(87.79±3.73)%,回收率达到(65.74±10.37)%。10名患者全部顺利造血重建,感染发生率50%(5/10例),复发率为20%(2/10例)。结论利用CliniMACS系统进行外周血CD34+细胞分选,CD34+细胞纯度、回收率均满意,自体移植后造血功能重建顺利,近期疗效满意。
Objective To analyze the clinical efficacy of autologous purified CD34 + cells in the treatment of malignant tumors of middle / high risk lymphocytes. Methods Ten patients with malignant tumor of lymphocyte originated from high risk group were treated with autologous purified CD34 + cells. The cells were sorted by cliniMACS system. The purity and the recovery rate of CD34 + cells were calculated and analyzed, and the complication and patient survival were observed. Results After purification, the purity of CD34 + cells was (87.79 ± 3.73)% and the recovery rate was (65.74 ± 10.37)%. All 10 patients were successfully hematopoietic reconstructed. The incidence of infection was 50% (5/10 cases) and the recurrence rate was 20% (2/10 cases). Conclusion CliniMACS system was used to perform CD34 + cell sorting in peripheral blood. The purity and recovery rate of CD34 + cells were satisfactory. The hematopoietic function reconstructed smoothly after autologous transplantation, and the curative effect was satisfactory in the near future.